CMX001-304: A Phase 3, Open-label, Multicenter Study of the Safety/Tolerability and Efficacy of Brincidofovir(CMX001) for the Prevention of Adenovirus (AdV) Disease in Subjects with Asymptomatic AdV Infection at Risk of Progres

Project: Research project

Project Details

StatusFinished
Effective start/end date6/1/159/20/20

Funding

  • Chimerix, Inc.